At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 109 enrolled
Drug / intervention
Adavosertibdrug
Likely dose
Adavosertib 300 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2b, Open-label, Single-arm, Multi-centre Study Assessing the Efficacy and Safety of Adavosertib as Treatment for Recurrent or Persistent Uterine Serous Carcinoma
In Brief
A Phase 2 clinical trial evaluating Adavosertib for Uterine Serous Carcinoma. Completed, enrolled 109 participants across 27 sites in 5 countries.
Detailed Summary
This Phase 2b study aims to evaluate the efficacy and safety of adavosertib, an inhibitor of the tyrosine kinase WEE1, in subjects with recurrent or persistent uterine serous carcinoma (USC) who have previously received at least 1 prior platinum-based chemotherapy regimen for the management of USC.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsUterine Serous Carcinoma
CountriesCanada, France, Italy, Spain, United States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedOct 2020
Enrollment StartNov 2020
Primary CompletionMay 2022
Study CompletionFeb 2023
TodayJul 2026
First PostedOct 19, 2020
Enrollment StartNov 30, 2020
Primary CompletionMay 23, 2022
Study CompletionFeb 7, 2023
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 5.7 years ago
Interventions
Adavosertibdrug
The subjects will receive oral adavosertib 300 mg, once daily on Days 1 to 5 and Days 8 to 12 of a 21-day treatment cycle.